Suppr超能文献

IDH 1/2 突变且无 1p/19q 共缺失的 WHO Ⅲ级胶质瘤患者行全切除的影响

Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.

作者信息

Kawaguchi Tomohiro, Sonoda Yukihiko, Shibahara Ichiyo, Saito Ryuta, Kanamori Masayuki, Kumabe Toshihiro, Tominaga Teiji

机构信息

Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Department of Neurosurgery, Faculty of Medicine, Yamagata University School of Medicine, 2-2-2 Iidanishi, Yamagata, Yamagata, 990-9585, Japan.

出版信息

J Neurooncol. 2016 Sep;129(3):505-514. doi: 10.1007/s11060-016-2201-2. Epub 2016 Jul 11.

Abstract

The prognosis of patients with WHO grade III gliomas is highly dependent on their genomic status such as the isocitrate dehydrogenase (IDH) 1/2 mutation and1p/19q co-deletion. However, difficulties have been associated with determining which tumors have certain genomic profiles by preoperative radiographical modalities, and the role of surgical resection in achieving better outcomes remains unclear. This retrospective study included 124 consecutive patients with newly diagnosed grade III gliomas. The genomic status of IDH1/2 and 1p/19q was analyzed in these patients. Tumors were then divided into 3 subgroups based on their genomic status; the IDH 1/2 mutation with the 1p/19q co-deletion (1p/19q co-del), the IDH 1/2 mutation without the 1p/19q co-deletion (non-1p/19q co-del), and the IDH 1/2 wild type (IDH wt). Survival times were compared between patients who underwent gross total resection and those who did not (GTR versus non-GTR). The relationships between genomic statuses and MR imaging characteristics such as ring-like or nodular enhancements by gadolinium, and very low intensity on T1-weighted images with blurry enhancements (T1VL) were also examined. Among all patients with grade III gliomas, GTR patients had longer median survival and progression-free times than those of non-GTR patients (undefined versus 87 months, p = 0.097, and 124 versus 34 months, p = 0.059, respectively). No significant differences were observed in survival between GTR and non-GTR patients in the 1p/19q co-del group (p = 0.14), or between GTR and non-GTR patients in the IDH wt group (26 and 27 months, p = 0.29). On the other hand, in non-1p/19q co-del group, survival was significantly longer in GTR patients than in non-GTR patients (undefined versus 77 months, p = 0.005). Radiographically, T1VL was detected in most tumors in the non-1p/19q co-del group (78.2 %), but only 6 (21.4 %) and 17 (41.5 %) tumors in the 1p/19q co-del and IDH wt groups, respectively. A correlation was not found between other genomic subgroups and MR imaging findings. Strict surgical removal is important to improve the prognosis of patients with grade III gliomas, especially for tumors with the IDH 1/2 mutation without the 1p/19q co-deletion. The MR finding of T1VL can be used to select candidates for more radical resection.

摘要

世界卫生组织(WHO)III级胶质瘤患者的预后高度依赖于其基因组状态,如异柠檬酸脱氢酶(IDH)1/2突变和1p/19q共缺失。然而,通过术前影像学手段确定哪些肿瘤具有特定的基因组特征存在困难,手术切除在实现更好预后方面的作用仍不明确。这项回顾性研究纳入了124例连续的新诊断III级胶质瘤患者。分析了这些患者的IDH1/2和1p/19q基因组状态。然后根据基因组状态将肿瘤分为3个亚组:IDH 1/2突变伴1p/19q共缺失(1p/19q共缺失)、IDH 1/2突变不伴1p/19q共缺失(非1p/19q共缺失)和IDH 1/2野生型(IDH野生型)。比较了接受全切除和未接受全切除的患者(全切除与非全切除)的生存时间。还研究了基因组状态与磁共振成像特征之间的关系,如钆增强后的环状或结节状强化,以及T1加权图像上极低信号伴模糊强化(T1VL)。在所有III级胶质瘤患者中,全切除患者的中位生存期和无进展生存期均长于非全切除患者(未定义与87个月,p = 0.097;124与34个月,p = 0.059)。在1p/19q共缺失组中,全切除和非全切除患者的生存率无显著差异(p = 0.14),在IDH野生型组中,全切除和非全切除患者的生存率也无显著差异(26和27个月,p = 0.29)。另一方面,在非1p/19q共缺失组中,全切除患者的生存期明显长于非全切除患者(未定义与77个月,p = 0.005)。影像学上,非1p/19q共缺失组的大多数肿瘤(78.2%)检测到T1VL,但1p/19q共缺失组和IDH野生型组分别只有6例(21.4%)和17例(41.5%)肿瘤检测到T1VL。未发现其他基因组亚组与磁共振成像结果之间存在相关性。严格的手术切除对于改善III级胶质瘤患者的预后很重要,特别是对于IDH 1/2突变且无1p/19q共缺失的肿瘤。T1VL的磁共振成像表现可用于选择更激进切除的候选患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验